700098Point of Care testing device for delivery of automated screening for disease via retinal images for worldwide healthcare deployment.ClosedGRD Proof of MarketInnovate UKScreening for Diabetic Retinopathy (DR) helps reduce the incidence of blindness in people with diabetes, but cost effective screening programmes can only be achieved with automation. To address this Medalytix is looking to develop a Point Of Care Testing (POCT) device for delivery of automated screening for diseases via retinal images. The POCT device will be costeffective and portable but will need sufficient battery power to work remotely for long periods. Success in the project will open up the ability to deliver safe and effective screening programmes globally, using UK-based technology to address the problem of the world’s leading causes of blindness (DR and AMD) and one of the world’s leading causes of mortality (CVD). Improved early detection of at risk patients through provision of the ability to screen in convenient locations (retail/pharmacy/GP) will allow improved patient management, speed up the time to result and treatment and ultimately deliver cost savings to the healthcare system via more widespread screening of the population. The Grant for R&D Proof of Market will be used to work with an independent market and commercialisation specialist firm for conducting a formal market research and will provide the required funding to help Medalytix establish a full validation of the global market, gaining a thorough understanding of the needs and requirements of end-users and develop a solid business case.